Unanimous Court Rules Confidential Sales Can Invalidate Patent as Prior Art
In Helsinn Healthcare S.A. v Teva Pharmaceuticals USA Inc., 586 U. S. ____ (2019), the U.S. Supreme Court unanimously held that a commercial sale to a third party who is required to keep the invention confidential may place the invention “on sale” under the Leahy-Smith America Invents Act (AIA). Pursuant to the on-sale bar, an invention is ineligible for patent protection if it has been offered for sale for over one year prior to the patent filing.
History of the On-Sale Bar
Historically, the on-sale bar applied to any sale of an invention, even if the sale was conducted privately. In Pfaff v. Wells Electronics, Inc., 525 U.S. 55 (1998), the Supreme Court held that two conditions must be satisfied for the on-sale bar to apply: first, “the product must be the subject of a commercial offer for sale,” and, second, “the invention must be ready for patenting.”
In overhauling U.S. patent law, the AIA redefined prior art, including the on-sale bar. As amended by the AIA, 35 U.S.C. 102(b) now states:
A person shall be entitled to a patent unless— (1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
The question before the Court was whether changing the definition of the on-sale bar also altered whether it applied to confidential sales of the later-patented invention.
Facts of Helsinn Healthcare S.A. v Teva Pharmaceuticals USA Inc.
Helsinn’s flagship drug, Aloxi®, which is used to treat cancer patients suffering from chemotherapy-induced nausea and vomiting. The patents-in-suit purport to disclose novel intravenous formulations using unexpectedly low concentrations of palonosetron that were not taught by the prior art. All four of the patents-in-suit claim priority to a provisional patent application filed on January 30, 2003. Thus, the critical date for the on-sale bar is one year earlier, January 30, 2002.
In 2001, Helsinn entered a license agreement and a supply and purchase agreement with MGI Pharma. Under the agreements, MGI agreed to make upfront payments, and to pay future royalties if Helsinn’s products obtained approval from the U.S. Food and Drug Administration (FDA). The agreements, which described the 0.25 and 0.75 mg palonosetron doses, bound MGI to keep confidential petitioner’s proprietary knowledge related to the products, including the proposed novel formulations. As a public company, MGI was required to file a Form 8-K with the Securities and Exchange Commission (SEC) disclosing the agreements. While MGI attached the agreements to the filing, it redacted the covered palonosetron formulations, consistent with its contractual obligation. Helsinn and MGI simultaneously announced the agreements in a press release, again omitting the details of the palonosetron formulations.
In 2011, Teva Pharmaceuticals USA, Inc. (Teva) filed an abbreviated new drug application (ANDA) seeking FDA approval to market a generic version of Helsinn’s 0.25 mg palonosetron product. Its ANDA included a so-called “Paragraph IV” certification that Helsinn’s patents were invalid or would not be infringed by Teva’s generic version. Pursuant to the Hatch-Waxman Act, Helsinn filed a patent infringement action.
The District Court held that the AIA’s “on sale” provision did not apply because the public disclosure of the agreements did not disclose the 0.25 mg dose. The Federal Circuit reversed, holding that the sale was publicly disclosed, regardless of whether the details of the invention were publicly disclosed in the terms of the sale agreements.
Supreme Court’s Decision in Helsinn Healthcare S.A. v Teva Pharmaceuticals USA Inc.
The Supreme Court unanimously affirmed the Federal Circuit’s decision. “[A] commercial sale to a third party who is required to keep the invention confidential may place the invention ‘on sale’ under the AIA,” Justice Clarence Thomas wrote on behalf of the Court.
Citing Pfaff, the Court noted that its precedent interpreting patent statute in force immediately before the AIA supports the view that a sale or offer of sale need not make an invention available to the public to constitute invalidating prior art. It also highlighted that the Federal Circuit has expressly held that “secret sales” could invalidate a patent.
It further concluded that the AIA did not alter the meaning of the “on sale” bar. “In light of this settled pre-AIA precedent on the meaning of ‘on sale,’ we presume that when Congress reenacted the same language in the AIA, it adopted the earlier judicial construction of that phrase,” Justice Thomas wrote.
Finally, the Court concluded that the addition of the catchall phrase “or otherwise available to the public” is not enough of a change for the Court to conclude that Congress intended to alter the meaning of “on sale.” Justice Thomas explained:
As amicus United States noted at oral argument, if “on sale” had a settled meaning before the AIA was adopted, then adding the phrase “or otherwise available to the public” to the statute “would be a fairly oblique way of attempting to overturn” that “settled body of law.” Tr. of Oral Arg. 28. The addition of “or otherwise available to the public” is simply not enough of a change for us to conclude that Congress intended to alter the meaning of the reenacted term “on sale.”
Second Amendment Back at Supreme Courtby DONALD SCARINCI on December 4, 2023
The U.S. Supreme Court recently heard oral arguments in its first significant Second Amendment case...
SCOTUS Tackles Key Constitutional Issues as It Kicks Off November Sessionby DONALD SCARINCI on November 29, 2023
The U.S. Supreme Court resumed oral arguments on October 30, as it begins its November session. The...
SCOTUS to Determine Future of Chevron Deferenceby DONALD SCARINCI on November 20, 2023
The U.S. Supreme Court has now granted certiorari in two cases challenging the continued viability ...
- Establishment ClauseFree Exercise Clause
- Freedom of Speech
- Freedoms of Press
- Freedom of Assembly, and Petitition
- The Right to Bear Arms
- Unreasonable Searches and Seizures
- Due Process
- Eminent Domain
- Rights of Criminal Defendants
Preamble to the Bill of Rights
Congress of the United States begun and held at the City of New-York, on Wednesday the fourth of March, one thousand seven hundred and eighty nine.
THE Conventions of a number of the States, having at the time of their adopting the Constitution, expressed a desire, in order to prevent misconstruction or abuse of its powers, that further declaratory and restrictive clauses should be added: And as extending the ground of public confidence in the Government, will best ensure the beneficent ends of its institution.